Formulation, evaluation and optimization of transdermal patches of losartan potassium
The aim of the study was to design and evaluate transdermal patches of losartan potassium in the treatment of Congestive heart failure. Transdermal patches were fabricated by solvent casting technique using Hydroxy Propyl Methyl Cellulose (HPMC), Carbopol (CP), Polyvinyl Pyrrolidone (PVP) and plasticizer to make the extended controlled release formulation. In the present study, total thirteen formulations were subjected to various evaluation parameters. Based on the evaluation results, it was concluded that swelling index was found to be proportional to HPMC and inversely proportional to carbopol. Formulation Patch F2 showed highest 39.55 % swelling index due to higher amount of HPMC. The results from in vitro drug release shows that the release of drug from patches increase with increase in concentration of HPMC. The formulation F6 exhibited maximum (93.41% )percentage drug release value in 8 hrs, which is compared to the minimum values obtained with the formulation F3 (61.77%). Optimized formulation will be evaluated on the basis of kinetic modeling studies. The % CDR and % S.I of the optimized batch was found 91.74% and 35.24% respectively. The results indicated that the permeation was good in HOP (HPMC-CP) transdermal patches and about 70.65 % of drug could permeate the membrane in 8 hrs and make the transdermal patches of losartan potassium as a good choice to bypass the undesirable systemic side effects and can be proposed as a new therapeutic tool in treating hypertensive patients.
Full Text Attachment